Verona's ensifentrine misses in Phase II for COPD maintenance

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) said both doses of ensifentrine (RPL554) given on top of dual bronchodilator therapy missed the primary endpoint in a

Read the full 240 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE